title: Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine.
abstract: We described the population pharmacokinetics of moxifloxacin and the effect of high-dose intermittent rifapentine in patients with pulmonary tuberculosis who were randomized to a continuation-phase regimen of 400 mg moxifloxacin and 900 mg rifapentine twice weekly or 400 mg moxifloxacin and 1,200 mg rifapentine once weekly. A two-compartment model with transit absorption best described moxifloxacin pharmacokinetics. Although rifapentine increased the clearance of moxifloxacin by 8% during antituberculosis treatment compared to that after treatment completion without rifapentine, it did not result in a clinically significant change in moxifloxacin exposure.
authors.affiliation: Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
authors.forename: Simbarashe P
authors.initials: SP
authors.lastname: Zvada
authors.forename: Paolo
authors.initials: P
authors.lastname: Denti
authors.forename: Hennie
authors.initials: H
authors.lastname: Geldenhuys
authors.forename: Sandra
authors.initials: S
authors.lastname: Meredith
authors.forename: Danelle
authors.initials: D
authors.lastname: van As
authors.forename: Mark
authors.initials: M
authors.lastname: Hatherill
authors.forename: Willem
authors.initials: W
authors.lastname: Hanekom
authors.forename: Lubbe
authors.initials: L
authors.lastname: Wiesner
authors.forename: Ulrika S H
authors.initials: US
authors.lastname: Simonsson
authors.forename: Amina
authors.initials: A
authors.lastname: Jindani
authors.forename: Thomas
authors.initials: T
authors.lastname: Harrison
authors.forename: Helen M
authors.initials: HM
authors.lastname: McIlleron
mesh_terms: D000328:Adult; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage* / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001372:Aza Compounds / Q000097:blood* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D024841:Fluoroquinolones; D006801:Humans; D000077266:Moxifloxacin; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D011804:Quinolines / Q000097:blood* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D012293:Rifampin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin; D012293:Rifampin; C018421:rifapentine